The present invention relates to a fusion protein in which a target protein and an Oct-1 protein-containing protein tag are linked, an expression structure comprising a nucleotide sequence encoding same, a recombinant vector including same, and a transformed cell including same.

The present disclosure relates to cellular compositions that are modified to introduce a nucleic acid or vector expressing the same. Such compositions may be used to deliver nucleic acid to a target cell and treat disease such as cancer.

The present disclosure provides, inter alia, compositions and methods for enforcing a pattern of cell surface fucosylated lactosaminyl glycans on a human cell. In certain embodiments, the compositions and/or methods utilize one or more members of the (1,3)-fucosyltransferase family. In certain embodiments, a process for custom-modifying a fucosylated lactosaminyl glycan on a human cell is disclosed.

Provided are methods for recombinantly producing enzymatically active glycosyltransferase (GT) enzymes. Active recombinant glycosyltransferase enzymes and method of use thereof are also provided. The methods for recombinantly producing enzymatically active GTs relies on a yeast expression system, preferably, a Pichia pastoris, expression system and more preferably, a Pichia pastoris stain with an ade2 deletion. Recombinantly produced enzymatically active GT enzymes produced according to the methods disclosed herein can be used for cell surface glycan engineering. The method includes contacting a cell with the disclosed compositions comprising purified recombinant GT enzyme and a substrate (nucleotide sugar) for the GT enzyme for an effective time for the GT enzyme to catalyze transfer of its substrate onto an acceptor site at the surface of the cell. The composition in preferred embodiments does not include glycerol as a stabilizer or it includes at least 50% glycerol.

The present disclosure provides, inter alia, compositions and methods for enforcing a pattern of cell surface fucosylated lactosaminyl glycans on a human cell. In certain embodiments, the compositions and/or methods utilize one or more members of the ?(1,3)-fucosyltransferase family. In certain embodiments, a process for custom-modifying a fucosylated lactosaminyl glycan on a human cell is disclosed.

The present invention provides methods of enforcing expression of an E-selectin and/or L-selectin ligand on a surface of a cell. Also provided are methods of enabling and/or increasing binding of a cell to E-selectin and/or L-selectin, methods of increasing homing and/or extravasation in a population of transplanted cells, methods of producing modified cells, including stem cells, for transplanting into a subject, methods of treating or ameliorating the effects of a symptom, a disease or an injury in a subject, and methods for inducing and/or enhancing homing of a population of cells to a therapeutic target in a subject. The invention further provides pharmaceutical compositions comprising a population of cells produced by the methods of the invention and kits that include such compositions for treating or ameliorating the effects of a symptom, a disease or an injury in a subject.

The present invention relates to a nucleic acid molecule encoding a) a modified tyrosylprotein sulfotransferase of a wildtype tyrosylprotein sulfotransferase, wherein the cytoplasmic transmembrane stem (CTS) region of the wild-type tyrosylprotein sulfotransferase is replaced by a heterologous CTS region, or b) a fusion protein comprising a catalytically active fragment of a tyrosylprotein sulfotransferase fused to a heterologous CTS region.

The present invention relates to modified cancer cell lines, wherein the ST3Gal1 glycosyltransferase expression is reduced or inhibited. The use of the modified cancer cell lines with suppressed ST3Gal1 glycosyltransferase to screen a potential cancer therapeutic is provided. The suppression of ST3Gal1 glycosyltransferase expression, with or without an anti-cancer agent is also provided to inhibit the growth of cancer cells in a subject.

Provided herein are methods and recombinant expression systems for the production of recombinant glycoproteins that have increased sialic acid content and contain predominantly alpha2-6 sialic acid linkages. Also provided herein are recombinant glycoproteins that have an increased in vivo circulatory half-life. One potential application of the glycoproteins described herein is for the treatment and prophylaxis of poisoning by neurotoxins.

The present disclosure relates to cellular compositions that are modified to introduce a nucleic acid or vector expressing the same. Such compositions may be used to deliver nucleic acid to a target cell and treat disease such as cancer.